• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Mark Zitter, MBA, Discusses Oncology Pathways

Article

Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs.

Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs. However, Zitter says that over the next year or so, pathways will not be the dominant factor in oncology management.

Related Videos
Ken Cohen, MD, FACP, executive director of translational research, Optum Health
James Simon, MD – Image credit: AJMC
Brooke Aggarwal, EdD – screenshot by AJMC
Hearn Jay Cho, MD, PhD
Susan Cantrell, CEO of AMCP
Related Content
The real-world data support the long-term value of mepolizumab as an add-on maintenance therapy in severe asthma. | gustavofrazao - stock.adobe.com

Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma

October 26th 2025
Article

The real-world data support the long-term value of mepolizumab as an add-on maintenance therapy in severe asthma.

Read More

The Evolution of AI Models in Mammography With Robert Nishikawa, PhD

The Evolution of AI Models in Mammography With Robert Nishikawa, PhD

October 23rd 2025
Podcast

AI-powered mammography is enhancing breast cancer screening and early detection through cutting-edge radiology insights.

Listen

Counselor soothing traumatized patient | Image credit: Rakchanok – stock.adobe.com

How Can Trauma Affect the Menopausal Transition?

October 25th 2025
Article

Early and lifelong trauma can intensify menopause symptoms and accelerate cardiovascular and brain aging, according to research.

Read More

Challenges, Opportunities in Implementing the MDPP: Melanie T. Turk, PhD, RN

Challenges, Opportunities in Implementing the MDPP: Melanie T. Turk, PhD, RN

October 21st 2025
Podcast

Melanie T. Turk, PhD, RN, discusses her study on nationwide challenges program suppliers face in implementing the Medicare Diabetes Prevention Program (MDPP).

Listen

Those with moderately increased baseline levels of CD45 + C1q + CCR8+ cells had a markedly higher risk of disease progression than those with lower levels. | Crystal light - stock.adobe.com

New Immune Cell Marker Offers Clues to Kidney Disease Progression

October 25th 2025
Article

CD45 + C1q + CCR8+ cells were found to be a novel immune-cell subset associated with kidney disease severity and progression risk.

Read More

Raman spectroscopy represents a promising approach to analyze dried serum from patients with CLL. | Image credit: Artur Wnorowski - stock.adobe.com

Serum Spectroscopy Reveals Prognostic Risk Factors in CLL

October 24th 2025
Article

Serum biochemical fingerprints can stratify chronic lymphocytic leukemia (CLL) outcomes and uncover heterogeneity within molecularly defined low-risk disease.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.